Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $393,000.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 10,000 shares of the stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $39.30, for a total value of $393,000.00. Following the completion of the sale, the insider now owns 95,034 shares in the company, valued at approximately $3,734,836.20. This trade represents a 9.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Tuesday, April 15th, Catriona Yale sold 9,073 shares of Akero Therapeutics stock. The shares were sold at an average price of $37.91, for a total value of $343,957.43.
• On Monday, March 17th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.76, for a total value of $447,600.00.
• On Wednesday, March 12th, Catriona Yale sold 614 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.88, for a total value of $27,556.32.
• On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $49.87, for a total value of $498,700.00.

Akero Therapeutics Price Performance

AKRO stock traded down $0.73 during midday trading on Monday, reaching $38.14. The company had a trading volume of 740,553 shares, compared to its average volume of 911,058. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of -10.17 and a beta of -0.12. The stock has a 50 day moving average price of $40.85 and a 200-day moving average price of $37.88. Akero Therapeutics, Inc. has a 1-year low of $17.86 and a 1-year high of $58.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.01) by $1.91. Equities research analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Analysts Set New Price Targets

AKRO has been the subject of a number of research reports. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. HC Wainwright lifted their target price on Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Canaccord Genuity Group lifted their target price on Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Morgan Stanley reissued an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Finally, UBS Group boosted their price target on Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $82.33.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. grew its holdings in shares of Akero Therapeutics by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 1,787 shares of the company’s stock worth $72,000 after purchasing an additional 321 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Akero Therapeutics by 14.5% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,664 shares of the company’s stock worth $114,000 after purchasing an additional 338 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Akero Therapeutics by 30.8% during the first quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company’s stock worth $67,000 after purchasing an additional 390 shares during the last quarter. Amalgamated Bank grew its holdings in shares of Akero Therapeutics by 19.0% during the first quarter. Amalgamated Bank now owns 2,570 shares of the company’s stock worth $104,000 after purchasing an additional 410 shares during the last quarter. Finally, Summit Investment Advisors Inc. grew its holdings in shares of Akero Therapeutics by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock worth $197,000 after purchasing an additional 450 shares during the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.